Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 19.90
+0.19 (0.96%)
Apr 29, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Market Capitalization | 7,915 | 7,963 | 8,811 | 12,808 | 21,257 | 42,401 | Upgrade
|
| Market Cap Growth | -17.19% | -9.63% | -31.21% | -39.74% | -49.87% | - | Upgrade
|
| Enterprise Value | 5,975 | 6,100 | 6,995 | 10,670 | 18,877 | 41,383 | Upgrade
|
| Last Close Price | 19.90 | 20.02 | 22.02 | 31.61 | 50.47 | 100.29 | Upgrade
|
| PE Ratio | - | - | - | - | 35.77 | 62.51 | Upgrade
|
| Forward PE | 48.54 | 74.62 | 43.69 | 48.03 | 23.21 | 57.10 | Upgrade
|
| PS Ratio | 5.60 | 5.78 | 6.40 | 9.96 | 5.96 | 22.69 | Upgrade
|
| PB Ratio | 2.09 | 2.10 | 2.23 | 3.18 | 4.61 | 10.27 | Upgrade
|
| P/TBV Ratio | 2.21 | 2.23 | 2.37 | 3.37 | 4.80 | 10.32 | Upgrade
|
| P/FCF Ratio | 47.15 | 42.86 | - | - | - | 119.49 | Upgrade
|
| P/OCF Ratio | 37.75 | 34.15 | - | 83.72 | 28.91 | 68.74 | Upgrade
|
| EV/Sales Ratio | 4.23 | 4.43 | 5.08 | 8.30 | 5.29 | 22.15 | Upgrade
|
| EV/EBITDA Ratio | 64.72 | 85.36 | - | - | 20.66 | 54.37 | Upgrade
|
| EV/EBIT Ratio | - | - | - | - | 22.20 | 56.70 | Upgrade
|
| EV/FCF Ratio | 35.60 | 32.84 | - | - | - | 116.63 | Upgrade
|
| Debt / Equity Ratio | 0.27 | 0.22 | 0.19 | 0.32 | 0.10 | 0.02 | Upgrade
|
| Debt / EBITDA Ratio | 10.91 | 10.95 | 29.87 | - | 0.47 | 0.12 | Upgrade
|
| Debt / FCF Ratio | 6.00 | 4.54 | - | - | - | 0.26 | Upgrade
|
| Net Debt / Equity Ratio | -0.51 | -0.53 | -0.48 | -0.54 | -0.61 | -0.81 | Upgrade
|
| Net Debt / EBITDA Ratio | -22.25 | -28.15 | 109.47 | 12.62 | -3.07 | -4.42 | Upgrade
|
| Net Debt / FCF Ratio | -11.51 | -10.83 | 22.52 | 27.45 | 12.32 | -9.48 | Upgrade
|
| Asset Turnover | 0.27 | 0.27 | 0.26 | 0.22 | 0.67 | 0.60 | Upgrade
|
| Inventory Turnover | 1.17 | 1.19 | 1.24 | 1.45 | 4.59 | 2.08 | Upgrade
|
| Quick Ratio | 3.04 | 3.19 | 3.50 | 2.53 | 3.56 | 9.76 | Upgrade
|
| Current Ratio | 3.39 | 3.56 | 3.95 | 2.78 | 3.96 | 10.46 | Upgrade
|
| Return on Equity (ROE) | -0.58% | -0.58% | -0.49% | -1.69% | 13.58% | 24.85% | Upgrade
|
| Return on Assets (ROA) | -0.28% | -0.44% | -1.31% | -2.89% | 10.02% | 14.67% | Upgrade
|
| Return on Invested Capital (ROIC) | -1.28% | -1.88% | -5.83% | -14.91% | 64.41% | 119.81% | Upgrade
|
| Return on Capital Employed (ROCE) | -0.60% | -0.90% | -2.70% | -6.40% | 17.50% | 17.30% | Upgrade
|
| Earnings Yield | -0.18% | -0.21% | -0.21% | -0.55% | 2.80% | 1.60% | Upgrade
|
| FCF Yield | 2.12% | 2.33% | -0.96% | -0.62% | -1.07% | 0.84% | Upgrade
|
| Dividend Yield | 1.52% | - | 0.82% | 0.32% | 2.48% | 0.30% | Upgrade
|
| Payout Ratio | - | - | - | - | 22.25% | 0.66% | Upgrade
|
| Buyback Yield / Dilution | -29.79% | -14.77% | 8.20% | 1.16% | -9.95% | -1.97% | Upgrade
|
| Total Shareholder Return | -28.25% | -14.77% | 9.02% | 1.47% | -7.48% | -1.67% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.